{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T06:01:55Z","timestamp":1794290515154,"version":"4.9.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,29]],"date-time":"2020-06-29T00:00:00Z","timestamp":1593388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,29]],"date-time":"2020-06-29T00:00:00Z","timestamp":1593388800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","award":["115974"],"award-info":[{"award-number":["115974"]}],"id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Swedish Heart and Lung Foundation","award":["20160872"],"award-info":[{"award-number":["20160872"]}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"crossref","award":["2018-02837; 2009-1039"],"award-info":[{"award-number":["2018-02837; 2009-1039"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001729","name":"Swedish Foundation for Strategic Research","doi-asserted-by":"crossref","award":["LUDC-IRC 15-0067"],"award-info":[{"award-number":["LUDC-IRC 15-0067"]}],"id":[{"id":"10.13039\/501100001729","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000265","name":"UK Medical Research Council","doi-asserted-by":"crossref","award":["MR\/R02264X\/1"],"award-info":[{"award-number":["MR\/R02264X\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000291","name":"Kidney Research UK","doi-asserted-by":"crossref","award":["RP55\/2012"],"award-info":[{"award-number":["RP55\/2012"]}],"id":[{"id":"10.13039\/501100000291","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Diabetic kidney disease (DKD) remains one of the leading causes of premature death in diabetes. DKD is classified on albuminuria and reduced kidney function (estimated glomerular filtration rate (eGFR)) but these have modest value for predicting future renal status. There is an unmet need for biomarkers that can be used in clinical settings which also improve prediction of renal decline on top of routinely available data, particularly in the early stages. The iBEAt study of the BEAt-DKD project aims to determine whether renal imaging biomarkers (magnetic resonance imaging (MRI) and ultrasound (US)) provide insight into the pathogenesis and heterogeneity of DKD (primary aim) and whether they have potential as prognostic biomarkers in DKD (secondary aim).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      iBEAt is a prospective multi-centre observational cohort study recruiting 500 patients with type 2 diabetes (T2D) and eGFR \u226530\u2009ml\/min\/1.73m\n                      <jats:sup>2<\/jats:sup>\n                      . At baseline, blood and urine will be collected, clinical examinations will be performed, and medical history will be obtained. These assessments will be repeated annually for 3\u2009years. At baseline each participant will also undergo quantitative renal MRI and US with central processing of MRI images. Biological samples will be stored in a central laboratory for biomarker and validation studies, and data in a central data depository. Data analysis will explore the potential associations between imaging biomarkers and renal function, and whether the imaging biomarkers improve the prediction of DKD progression. Ancillary substudies will: (1) validate imaging biomarkers against renal histopathology; (2) validate MRI based renal blood flow measurements against H\n                      <jats:sub>2<\/jats:sub>\n                      O\n                      <jats:sup>15<\/jats:sup>\n                      positron-emission tomography (PET); (3) validate methods for (semi-)automated processing of renal MRI; (4) examine longitudinal changes in imaging biomarkers; (5) examine whether glycocalyx and microvascular measures are associated with imaging biomarkers and eGFR decline; (6) explore whether the findings in T2D can be extrapolated to type 1 diabetes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>iBEAt is the largest DKD imaging study to date and will provide valuable insights into the progression and heterogeneity of DKD. The results may contribute to a more personalised approach to DKD management in patients with T2D.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/clinicaltrials.gov\">Clinicaltrials.gov<\/jats:ext-link>\n                      (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03716401?term=iBEAT&amp;draw=2&amp;rank=2\">NCT03716401<\/jats:ext-link>\n                      ).\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12882-020-01901-x","type":"journal-article","created":{"date-parts":[[2020,6,29]],"date-time":"2020-06-29T09:03:52Z","timestamp":1593421432000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Prognostic imaging biomarkers for diabetic kidney disease (iBEAt): study protocol"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1825-9825","authenticated-orcid":false,"given":"Kim M.","family":"Gooding","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chrysta","family":"Lienczewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Papale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niina","family":"Koivuviita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlena","family":"Maziarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna-Maria","family":"Dutius Andersson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanishka","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Pontrelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Garcia Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kay","family":"Tobin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virva","family":"Saunavaara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Zetterqvist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Shelley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irvin","family":"Teh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Ball","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sapna","family":"Puppala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Ibberson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil","family":"Karihaloo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaj","family":"Mets\u00e4rinne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosamonde E.","family":"Banks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter S.","family":"Gilmour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Mansfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Gilchrist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dick","family":"de Zeeuw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiddo J. L.","family":"Heerspink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pirjo","family":"Nuutila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Kretzler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Welberry Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loreto","family":"Gesualdo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Andress","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Grenier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela C.","family":"Shore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria F.","family":"Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Sourbron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the BEAt-DKD consortium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,29]]},"reference":[{"issue":"9900","key":"1901_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/S0140-6736(13)62089-9","volume":"382","author":"V Jha","year":"2013","unstructured":"Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, et al. Chronic kidney disease: global dimension and perspectives. Lancet. 2013;382(9900):12\u20138.","journal-title":"Lancet."},{"issue":"12","key":"1901_CR2","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.2215\/CJN.03700417","volume":"12","author":"LR Zelnick","year":"2017","unstructured":"Zelnick LR, Weiss NS, Kestenbaum BR, Robinson-Cohen C, Heagerty PJ, Tuttle K, et al. Diabetes and CKD in the United States population, 2009\u20132014. Clin J Am Soc Nephrol. 2017;12(12):1984\u201390.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"12","key":"1901_CR3","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.2215\/CJN.11491116","volume":"12","author":"RZ Alicic","year":"2017","unstructured":"Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease: challenges, progress, and possibilities. Clin J Am Soc Nephrol. 2017;12(12):2032\u201345.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"1901_CR4","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.2337\/diacare.27.5.1047","volume":"27","author":"S Wild","year":"2004","unstructured":"Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27(5):1047\u201353.","journal-title":"Diabetes Care"},{"issue":"6","key":"1901_CR5","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1177\/1479164113500798","volume":"10","author":"MK Svensson","year":"2013","unstructured":"Svensson MK, Cederholm J, Eliasson B, Zethelius B, Gudbj\u00f6rnsdottir S. Albuminuria and renal function as predictors of cardiovascular events and mortality in a general population of patients with type 2 diabetes: a nationwide observational study from the Swedish National Diabetes Register. Diabetes Vasc Dis Res. 2013;10(6):520\u20139.","journal-title":"Diabetes Vasc Dis Res"},{"issue":"2","key":"1901_CR6","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/nrneph.2013.251","volume":"10","author":"SS Roscioni","year":"2014","unstructured":"Roscioni SS, Heerspink HJL, De Zeeuw D. The effect of RAAS blockade on the progression of diabetic nephropathy. Nat Rev Nephrol. 2014;10(2):77\u201387.","journal-title":"Nat Rev Nephrol."},{"issue":"Suppl. 2","key":"1901_CR7","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/j.1464-5491.2008.02496.x","volume":"25","author":"R Bilous","year":"2008","unstructured":"Bilous R. Microvascular disease: what does the UKPDS tell us about diabetic nephropathy? Diabet Med. 2008;25(Suppl. 2):25\u20139.","journal-title":"Diabet Med"},{"key":"1901_CR8","volume-title":"Biomarker Enterprise to Attack Diabetic Kidney Disease","author":"Lund University Diabetes Centre","year":"2019","unstructured":"Lund University Diabetes Centre. Biomarker Enterprise to Attack Diabetic Kidney Disease. 2019 . Available from: www.beat-dkd.org. [cited 2019 Aug 6]."},{"issue":"2","key":"1901_CR9","doi-asserted-by":"publisher","first-page":"ii4","DOI":"10.1093\/ndt\/gfy152","volume":"33","author":"NM Selby","year":"2018","unstructured":"Selby NM, Blankestijn PJ, Boor P, Combe C, Eckardt KU, Eikefjord E, et al. Magnetic resonance imaging biomarkers for chronic kidney disease: a position paper from the European Cooperation in Science and Technology Action PARENCHIMA. Nephrol Dial Transplant. 2018;33(2):ii4\u201314.","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"1901_CR10","doi-asserted-by":"publisher","first-page":"ii1","DOI":"10.1093\/ndt\/gfy181","volume":"33","author":"A Caroli","year":"2018","unstructured":"Caroli A, Pruijm M, Burnier M, Selby NM. Functional magnetic resonance imaging of the kidneys: where do we stand? The perspective of the European COST Action PARENCHIMA. Nephrol Dial Transplant. 2018;33(2):ii1\u20133.","journal-title":"Nephrol Dial Transplant"},{"key":"1901_CR11","volume-title":"Clinical review of PKD outcomes consortium biomarker qualification submissionle","author":"A Thompson","year":"2015","unstructured":"Thompson A. Clinical review of PKD outcomes consortium biomarker qualification submissionle. 2015. Available from: https:\/\/www.fda.gov\/media\/93159\/download."},{"key":"1901_CR12","unstructured":"CDER-BiomarkerQualificationProgram. List of Qualified Biomarkers [Internet]. Available from: https:\/\/www.fda.gov\/drugs\/cder-biomarker-qualification-program\/list-qualified-biomarkers. Accessed 6 Aug 2019."},{"issue":"6","key":"1901_CR13","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.7863\/ultra.32.6.1033","volume":"32","author":"M Mancini","year":"2013","unstructured":"Mancini M, Masulli M, Liuzzi R, Mainenti PP, Ragucci M, Maurea S, et al. Renal duplex sonographic evaluation of type 2 diabetic patients. J Ultrasound Med. 2013;32(6):1033\u201340.","journal-title":"J Ultrasound Med"},{"issue":"9","key":"1901_CR14","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.2337\/db06-0592","volume":"55","author":"G Zerbini","year":"2006","unstructured":"Zerbini G, Bonfanti R, Meschi F, Bognetti E, Paesano PL, Gianolli L, et al. Persistent renal hypertrophy and faster decline of glomerular filtration rate precede the development of microalbuminuria in type 1 diabetes. Diabetes. 2006;55(9):2620\u20135.","journal-title":"Diabetes."},{"key":"1901_CR15","doi-asserted-by":"crossref","unstructured":"Rigalleau V, Garcia M, Lasseur C, Laurent F, Montaudon M, Raffaitin C, et al. Large kidneys predict poor renal outcome in subjects with diabetes and chronic kidney disease. BMC Nephrol. 2010;11(3).","DOI":"10.1186\/1471-2369-11-3"},{"issue":"1","key":"1901_CR16","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1002\/jmri.10224","volume":"17","author":"M Ries","year":"2003","unstructured":"Ries M, Basseau F, Tyndal B, Jones R, Demini\u00e8re C, Catargi B, et al. Renal diffusion and BOLD MRI in experimental diabetic nephropathy. J Magn Reson Imaging. 2003;17(1):104\u201313.","journal-title":"J Magn Reson Imaging"},{"issue":"4","key":"1901_CR17","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1016\/j.kint.2017.10.020","volume":"93","author":"M Pruijm","year":"2018","unstructured":"Pruijm M, Milani B, Pivin E, Podhajska A, Vogt B, Stuber M, et al. Reduced cortical oxygenation predicts a progressive decline of renal function in patients with chronic kidney disease. Kidney Int. 2018;93(4):932\u201340.","journal-title":"Kidney Int"},{"key":"1901_CR18","doi-asserted-by":"crossref","unstructured":"Sugiyama K, Inoue T, Kozawa E, Ishikawa M, Shimada A, Kobayashi N, et al. Reduced oxygenation but not fibrosis defined by functional magnetic resonance imaging predicts the long-term progression of chronic kidney disease. Nephrol Dial Transplant. 2020;35(6):964\u201370.","DOI":"10.1093\/ndt\/gfy324"},{"key":"1901_CR19","doi-asserted-by":"publisher","first-page":"30088","DOI":"10.1038\/srep30088","volume":"6","author":"I Friedli","year":"2016","unstructured":"Friedli I, Crowe LA, Berchtold L, Moll S, Hadaya K, De Perrot T, et al. New magnetic resonance imaging index for renal fibrosis assessment: a comparison between diffusion-weighted imaging and T1 mapping with histological validation. Sci Rep. 2016;6:30088.","journal-title":"Sci Rep"},{"issue":"7","key":"1901_CR20","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1097\/RLI.0b013e31824f272d","volume":"47","author":"K Hueper","year":"2012","unstructured":"Hueper K, Hartung D, Gutberlet M, Gueler F, Sann H, Husen B, et al. Magnetic resonance diffusion tensor imaging for evaluation of histopathological changes in a rat model of diabetic nephropathy. Investig Radiol. 2012;47(7):430\u20137.","journal-title":"Investig Radiol"},{"issue":"5","key":"1901_CR21","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1159\/000333044","volume":"34","author":"L Lu","year":"2011","unstructured":"Lu L, Sedor JR, Gulani V, Schelling JR, O\u2019Brien A, Flask CA, et al. Use of diffusion tensor MRI to identify early changes in diabetic nephropathy. Am J Nephrol. 2011;34(5):476\u201382.","journal-title":"Am J Nephrol"},{"key":"1901_CR22","doi-asserted-by":"publisher","unstructured":"Berchtold L, Crowe LA, Friedli I, Legouis D, Moll S, de Perrot T, et al. Diffusion magnetic resonance imaging detects an increase in interstitial fibrosis earlier than the decline of renal function. Nephrol Dial Transplant. 2020. https:\/\/doi.org\/10.1093\/ndt\/gfaa007.","DOI":"10.1093\/ndt\/gfaa007"},{"issue":"6","key":"1901_CR23","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1002\/jmri.25717","volume":"46","author":"JM Mora-Guti\u00e9rrez","year":"2017","unstructured":"Mora-Guti\u00e9rrez JM, Garcia-Fernandez N, Slon Roblero MF, P\u00e1ramo JA, Escalada FJ, Wang DJJ, et al. Arterial spin labeling MRI is able to detect early hemodynamic changes in diabetic nephropathy. J Magn Reson Imaging. 2017;46(6):1810\u20137.","journal-title":"J Magn Reson Imaging"},{"issue":"4","key":"1901_CR24","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.cmet.2018.07.003","volume":"28","author":"R Taylor","year":"2018","unstructured":"Taylor R, Al-Mrabeh A, Zhyzhneuskaya S, Peters C, Barnes AC, Aribisala BS, et al. Remission of Human Type 2 Diabetes Requires Decrease in Liver and Pancreas Fat Content but Is Dependent upon Capacity for \u03b2 Cell Recovery. Cell Metab. 2018;28(4):547\u201356 e3.","journal-title":"Cell Metab"},{"key":"1901_CR25","unstructured":"National Kidney Foundation. K\/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 Suppl 1):S1\u2013S266."},{"issue":"4","key":"1901_CR26","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/ki.2012.428","volume":"83","author":"CA Gadegbeku","year":"2013","unstructured":"Gadegbeku CA, Gipson DS, Holzman LB, Ojo AO, Song PXK, Barisoni L, et al. Design of the nephrotic syndrome study network (NEPTUNE) to evaluate primary glomerular nephropathy by a multidisciplinary approach. Kidney Int. 2013;83(4):749\u201356.","journal-title":"Kidney Int"},{"issue":"1","key":"1901_CR27","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1159\/000487500","volume":"43","author":"S Eder","year":"2018","unstructured":"Eder S, Leierer J, Kerschbaum J, Rosivall L, Wiecek A, De Zeeuw D, et al. A prospective cohort study in patients with type 2 diabetes mellitus for validation of biomarkers (PROVALID) - study design and baseline characteristics. Kidney Blood Press Res. 2018;43(1):181\u201390.","journal-title":"Kidney Blood Press Res"},{"issue":"1","key":"1901_CR28","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.2517-6161.1996.tb02080.x","volume":"58","author":"R Tibshirani","year":"1996","unstructured":"Tibshirani R. Regression shrinkage and selection via the Lasso. J R Stat Soc Ser B. 1996;58(1):267\u201388.","journal-title":"J R Stat Soc Ser B"},{"issue":"2","key":"1901_CR29","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1111\/j.1467-9868.2005.00503.x","volume":"67","author":"H Zou","year":"2005","unstructured":"Zou H, Hastie T. Regularization and variable selection via the elastic net. J R Stat Soc Ser B Stat Methodol. 2005;67(2):301\u201320.","journal-title":"J R Stat Soc Ser B Stat Methodol"},{"issue":"4","key":"1901_CR30","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1681\/ASN.2010010010","volume":"21","author":"TWC Tervaert","year":"2010","unstructured":"Tervaert TWC, Mooyaart AL, Amann K, Cohen AH, TerenceCook H, Drachenberg CB, et al. Pathologic classification of diabetic nephropathy. J Am Soc Nephrol. 2010;21(4):556\u201363.","journal-title":"J Am Soc Nephrol"},{"key":"1901_CR31","volume-title":"Highlights from the BEAt-DKD symposium on precision medicine in diabetic kidney disease","author":"M Pena","year":"2019","unstructured":"Pena M. Highlights from the BEAt-DKD symposium on precision medicine in diabetic kidney disease. 2019. Available from: https:\/\/www.beat-dkd.eu\/download\/BEAt-DKD_WP6_Newsletter_May_2019_by_Michelle_Pena.pdf."},{"issue":"6","key":"1901_CR32","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1038\/nrneph.2016.44","volume":"12","author":"N Grenier","year":"2016","unstructured":"Grenier N, Merville P, Combe C. Radiologic imaging of the renal parenchyma structure and function. Nat Rev Nephrol. 2016;12(6):348\u201359.","journal-title":"Nat Rev Nephrol"},{"key":"1901_CR33","volume-title":"1st International Meeting on Renal MRI","author":"S Sourbron","year":"2015","unstructured":"Sourbron S, Grenier N. 1st International Meeting on Renal MRI. 2015. Available from: https:\/\/sites.google.com\/site\/renalmriworkshop\/. [cited 2019 Aug 18]."},{"key":"1901_CR34","volume-title":"2nd International Meeting on Renal MRI","author":"A Pohlmann","year":"2017","unstructured":"Pohlmann A, Seeliger E, Grosenick D, Waiczies S, Cantow K, Persson P, et al. 2nd International Meeting on Renal MRI. 2017. Available from: https:\/\/www.mdc-berlin.de\/renal. [cited 2019 Aug 18]."},{"key":"1901_CR35","unstructured":"Francis S, Selby N, Taal M. 3d International Meeting on Renal MRI [Internet]. Available from: https:\/\/www.nottingham.ac.uk\/research\/groups\/spmic\/research\/uk-renal-imaging-network\/3rd-renal-symposium\/3rd-international-symposium-on-functional-renal-imaging.aspx. Accessed 1 Nov 2019."},{"issue":"20","key":"1901_CR36","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1056\/NEJMoa054341","volume":"354","author":"JJ Grantham","year":"2006","unstructured":"Grantham JJ, Torres VE, Chapman AB, Guay-Woodford LM, Bae KT, King BF, et al. Volume progression in polycystic kidney disease. N Engl J Med. 2006;354(20):2122\u201330.","journal-title":"N Engl J Med"},{"issue":"1","key":"1901_CR37","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/mrm.26982","volume":"79","author":"KE Keenan","year":"2018","unstructured":"Keenan KE, Ainslie M, Barker AJ, Boss MA, Cecil KM, Charles C, et al. Quantitative magnetic resonance imaging phantoms: a review and the need for a system phantom. Magn Reson Med. 2018;79(1):48\u201361.","journal-title":"Magn Reson Med"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-020-01901-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-020-01901-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-020-01901-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T14:20:29Z","timestamp":1723126829000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-020-01901-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,29]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1901"],"URL":"https:\/\/doi.org\/10.1186\/s12882-020-01901-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.01.13.20017228","asserted-by":"object"}]},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,29]]},"assertion":[{"value":"13 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study is being performed in accordance with the principles of the Declaration of Helsinki and each recruiting centre has ethical approval from their local Ethical review committee (Leeds\/Sheffield: study was approved by Yorkshire & The Humber - South Yorkshire Research Ethics Committee, ref.: 18\/YH\/0077; Exeter: study was approved by South West - Exeter Research Ethics Committee, reference 18\/SW\/0061; Turku: study approved by Ethical committee of Hospital District of South West Finland, reference: 123 \/1801\/2017; Bordeaux: Study approved by CPP Est II, ref.: 18\/581; Bari: study approved by Independent Ethics Committee of the Policlinic Hospital in Bari, ref.: 5760). Written, informed consent to participate in this study is being obtained from all participants, in line with local guidelines.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"This work forms part of the BEAt-DKD consortium that is funded by the IMI 2 Joint Undertaking that receives support from the European Federation of Pharmaceutical Industries and Associations (EFPIA). BEAt-DKD EFPIA partners that have contributed to the iBEAT study development are Astellas, AbbVie and Novo Nordisk. JDRF also contributed to the iBEAT study design. AMDA reports grants from Boehringer Ingelheim Pharma GmbH during the conduct of the study. AZ reports non-financial support and other from Boehringer Ingelheim Pharma GmbH during the conduct of the study. MG reports personal fees from Lilly and other from Sanofi Genzyme, outside of the submitted work. DZ reports other from Fresenius, other from Boehringer Ingelheim, other from Bayer, other from Mitsubishi Tanabe, other from Mundipharma, other from Janssen, other from AbbVie, outside the submitted work. HJLH reports other from Merck, other from Mitsubishi Tanabe, grants and other from Janssen, other from Mundipharma, other from Gilead, grants and other from AstraZeneca, grants and other from Abbvie, other from Retrophin, outside the submitted work. MK reports grants from NIH, non-financial support from University of Michigan, during the conduct of the study; grants from JDRF, grants from Astra-Zeneca, grants from NovoNordisc, grants from Eli Lilly, grants from Gilead, grants from Goldfinch Bio, grants from Merck, grants from Janssen, grants from Boehringer-Ingelheim, outside the submitted work; In addition, MK has a patent Biomarkers for CKD progression (encompassing urinary EGF as biomarker of CKD progression) issued. DA reports other from AbbVie, outside the submitted work. MFG reports non-financial support and other from Boehringer Ingelheim Pharma GmbH, non-financial support and other from JDRF International, non-financial support and other from Eli Lilly, non-financial support and other from AbbVie, non-financial support and other from Sanofi-Aventis, non-financial support and other from Astellas, non-financial support and other from Novo Nordisk A\/S, non-financial support and other from Bayer AG, during the conduct of the study; personal fees from Lilly, non-financial support and other from Novo Nordisk, non-financial support and other from Pfizer, non-financial support and other from Follicum, non-financial support and other from Abcentra, non-financial support from Probi, non-financial support from Johnson & Johnson, outside the submitted work. SS reports non-financial support from Siemens, during the conduct of the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"242"}}